VERTEX PHARMACEUTICALS INC / MA Amortization of Debt Discount (Premium)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2014-02-11
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for the quarter ending 2011-12-31 was $6.55M, a 83.66% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for the quarter ending 2011-09-30 was $2.67M, a 22.66% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for the quarter ending 2011-06-30 was $2.58M, a 22.67% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for the quarter ending 2011-03-31 was $6.61M, a 104.43% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for fiscal 2013 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for fiscal 2011 was $18.41M, a 35.47% increase from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA amortization of debt discount (premium) for fiscal 2010 was $13.59M, a 334.85% increase from fiscal 2009.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-02-11 | |||
| 2011-12-31 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $9.22M derived: sum of 2 quarters · filed 2014-02-11 | $11.80M derived: sum of 3 quarters · filed 2014-02-11 | $18.41M 10-K · filed 2014-02-11 |
| 2011-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $5.25M derived: sum of 2 quarters · filed 2012-11-06 | $11.86M 10-Q · filed 2012-11-06 | $15.42M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $9.19M 10-Q · filed 2012-08-08 | $12.76M derived: sum of 3 quarters · filed 2013-03-01 | $16.21M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $6.61M 10-Q · filed 2012-05-10 | $10.17M derived: sum of 2 quarters · filed 2013-03-01 | $13.62M derived: sum of 3 quarters · filed 2013-03-01 | $16.96M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.02M derived: sum of 2 quarters · filed 2013-03-01 | $10.36M derived: sum of 3 quarters · filed 2013-03-01 | $13.59M 10-K · filed 2013-03-01 |
| 2010-09-30 | $3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $6.79M derived: sum of 2 quarters · filed 2011-11-03 | $10.02M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $6.57M 10-Q · filed 2011-08-09 | ||
| 2010-03-31 | $3.23M 10-Q · filed 2011-05-06 | |||
| 2009-12-31 | $3.13M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |